University of Tasmania
COPD-108698-an-antagonist-of-the-platelet-activating-factor-receptor-inh_072016.pdf (2.05 MB)

An antagonist of the platelet-activating factor receptor inhibits adherence of both nontypeable Haemophilus influenzae and Streptococcus pneumoniae to cultured human bronchial epithelial cells exposed to cigarette smoke

Download (2.05 MB)
journal contribution
posted on 2023-05-18, 21:05 authored by Shukla, SD, Fairbairn, RL, David GellDavid Gell, Roger Latham, Sukhwinder SohalSukhwinder Sohal, Eugene WaltersEugene Walters, O'Toole, RF
Background: COPD is emerging as the third largest cause of human mortality worldwide after heart disease and stroke. Tobacco smoking, the primary risk factor for the development of COPD, induces increased expression of platelet-activating factor receptor (PAFr) in the lung epithelium. Nontypeable Haemophilus influenza (NTHi) and Streptococcus pneumonia adhere to PAFr on the luminal surface of human respiratory tract epithelial cells.

Objective: To investigate PAFr as a potential drug target for the prevention of infections caused by the main bacterial drivers of acute exacerbations in COPD patients, NTHi and S. pneumonia.

Methods: Human bronchial epithelial BEAS-2B cells were exposed to cigarette smoke extract (CSE). PAFr expression levels were determined using immunocytochemistry and quantitative polymerase chain reaction. The epithelial cells were challenged with either NTHi or S. pneumonia labeled with fluorescein isothiocyanate, and bacterial adhesion was measured using immunofluorescence. The effect of a well-evaluated antagonist of PAFr, WEB-2086, on binding of the bacterial pathogens to BEAS-2B cells was then assessed. In silico studies of the tertiary structure of PAFr and the binding pocket for PAF and its antagonist WEB-2086 were undertaken.

Results: PAFr expression by bronchial epithelial cells was upregulated by CSE, and significantly associated with increased bacterial adhesion. WEB-2086 reduced the epithelial adhesion by both NTHi and S. pneumonia to levels observed for non-CSE-exposed cells. Furthermore, it was nontoxic toward the bronchial epithelial cells. In silico analyses identified a binding pocket for PAF/WEB-2086 in the predicted PAFr structure.

Conclusion: WEB-2086 represents an innovative class of candidate drugs for inhibiting PAFr-dependent lung infections caused by the main bacterial drivers of smoking-related COPD.


Publication title

International Journal of Chronic Obstructive Pulmonary Disease








Tasmanian School of Medicine


Dove Medical Press Ltd (Dovepress)

Place of publication

United Kingdom

Rights statement

© 2016 Shukla et al. Licensed under Creative Commons Attribution-NonCommercial 3.0 Unported (CC BY-NC 3.0)

Repository Status

  • Open

Socio-economic Objectives

Human pharmaceutical treatments

Usage metrics

    University Of Tasmania


    Ref. manager